annual cash & cash equivalents:
$2.93B-$1.24B(-29.72%)Summary
- As of today (August 23, 2025), GMAB annual cash & cash equivalents is $2.93 billion, with the most recent change of -$1.24 billion (-29.72%) on December 31, 2024.
- During the last 3 years, GMAB annual cash & cash equivalents has fallen by -$26.72 million (-0.90%).
- GMAB annual cash & cash equivalents is now -29.72% below its all-time high of $4.17 billion, reached on December 31, 2023.
Performance
GMAB Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$2.90B-$327.01M(-10.14%)Summary
- As of today (August 23, 2025), GMAB quarterly cash & cash equivalents is $2.90 billion, with the most recent change of -$327.01 million (-10.14%) on June 1, 2025.
- Over the past year, GMAB quarterly cash & cash equivalents has increased by +$637.99 million (+28.22%).
- GMAB quarterly cash & cash equivalents is now -32.32% below its all-time high of $4.28 billion, reached on March 31, 2024.
Performance
GMAB quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GMAB Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.7% | +28.2% |
| 3 y3 years | -0.9% | -4.6% |
| 5 y5 years | +77.8% | +50.5% |
GMAB Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.7% | at low | -32.3% | +28.2% |
| 5 y | 5-year | -29.7% | +77.8% | -32.3% | +50.5% |
| alltime | all time | -29.7% | +1569.9% | -32.3% | +1815.8% |
GMAB Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $2.90B(-10.1%) |
| Mar 2025 | - | $3.23B(+10.1%) |
| Dec 2024 | $2.93B(-29.7%) | $2.93B(+13.0%) |
| Sep 2024 | - | $2.59B(+14.7%) |
| Jun 2024 | - | $2.26B(-47.2%) |
| Mar 2024 | - | $4.28B(+2.7%) |
| Dec 2023 | $4.17B(+30.1%) | $4.17B(+6.7%) |
| Sep 2023 | - | $3.91B(+7.2%) |
| Jun 2023 | - | $3.65B(+1.9%) |
| Mar 2023 | - | $3.58B(+11.7%) |
| Dec 2022 | $3.20B(+8.4%) | $3.20B(+2.2%) |
| Sep 2022 | - | $3.13B(+3.1%) |
| Jun 2022 | - | $3.04B(+1.6%) |
| Mar 2022 | - | $2.99B(+1.1%) |
| Dec 2021 | $2.96B(+11.9%) | $2.96B(+1.2%) |
| Sep 2021 | - | $2.92B(+2.5%) |
| Jun 2021 | - | $2.85B(-0.2%) |
| Mar 2021 | - | $2.86B(+8.1%) |
| Dec 2020 | $2.64B(+60.4%) | $2.64B(-4.0%) |
| Sep 2020 | - | $2.75B(+42.9%) |
| Jun 2020 | - | $1.93B(+1.1%) |
| Mar 2020 | - | $1.91B(+15.6%) |
| Dec 2019 | $1.65B(+76.2%) | $1.65B(+1.5%) |
| Sep 2019 | - | $1.62B(+53.1%) |
| Jun 2019 | - | $1.06B(+3.2%) |
| Mar 2019 | - | $1.03B(+9.8%) |
| Dec 2018 | $935.38M(+7.0%) | $935.38M(+1.9%) |
| Sep 2018 | - | $918.24M(-3.5%) |
| Jun 2018 | - | $951.33M(+1.1%) |
| Mar 2018 | - | $940.65M(+7.6%) |
| Dec 2017 | $874.58M(+57.2%) | $874.58M(+6.2%) |
| Sep 2017 | - | $823.52M(+2.9%) |
| Jun 2017 | - | $799.96M(+17.1%) |
| Mar 2017 | - | $683.27M(+22.8%) |
| Dec 2016 | $556.34M(+9.4%) | $556.34M(-6.5%) |
| Sep 2016 | - | $595.00M(+5.9%) |
| Jun 2016 | - | $561.78M(+5.2%) |
| Mar 2016 | - | $533.89M(+5.0%) |
| Dec 2015 | $508.49M(+17.6%) | $508.49M(+6.0%) |
| Sep 2015 | - | $479.65M(+8.6%) |
| Jun 2015 | - | $441.77M(+4.3%) |
| Mar 2015 | - | $423.39M(-2.1%) |
| Dec 2014 | $432.34M(+50.3%) | $432.34M(-3.4%) |
| Sep 2014 | - | $447.76M(-5.7%) |
| Jun 2014 | - | $474.58M(+1.6%) |
| Mar 2014 | - | $467.00M(+62.4%) |
| Dec 2013 | $287.58M | $287.58M(-4.0%) |
| Sep 2013 | - | $299.70M(+11.2%) |
| Jun 2013 | - | $269.54M(+5.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $256.54M(+26.1%) |
| Sep 2012 | - | $203.39M(+26.2%) |
| Jun 2012 | - | $161.17M(-11.6%) |
| Mar 2012 | - | $182.27M(-16.7%) |
| Sep 2011 | - | $218.75M(-13.5%) |
| Jun 2011 | - | $252.85M(-8.0%) |
| Mar 2011 | - | $274.94M(-7.4%) |
| Dec 2010 | $296.90M(+20.5%) | $296.90M(-3.9%) |
| Sep 2010 | - | $309.02M(+104.2%) |
| Jun 2010 | - | $151.33M(-22.4%) |
| Mar 2010 | - | $195.00M(-20.8%) |
| Dec 2009 | $246.36M(-25.1%) | $246.36M(-9.1%) |
| Sep 2009 | - | $271.00M(-2.4%) |
| Jun 2009 | - | $277.67M(+9.0%) |
| Mar 2009 | - | $254.71M(-22.6%) |
| Dec 2008 | $329.06M(-54.6%) | - |
| Dec 2008 | - | $329.06M(-16.6%) |
| Sep 2008 | - | $394.48M(-10.8%) |
| Jun 2008 | - | $442.28M(-12.2%) |
| Mar 2008 | - | $503.92M(-30.4%) |
| Dec 2007 | $724.21M(+137.4%) | - |
| Dec 2007 | - | $724.21M(-3.2%) |
| Sep 2007 | - | $748.14M(+3.6%) |
| Jun 2007 | - | $722.20M(-4.3%) |
| Mar 2007 | - | $754.36M(+147.3%) |
| Dec 2006 | $305.02M(+53.9%) | - |
| Dec 2006 | - | $305.02M(-3.4%) |
| Sep 2006 | - | $315.68M(-4.0%) |
| Jun 2006 | - | $328.71M(+0.9%) |
| Mar 2006 | - | $325.70M(+64.4%) |
| Dec 2005 | $198.13M(-6.4%) | - |
| Dec 2005 | - | $198.13M(-12.0%) |
| Sep 2005 | - | $225.21M(+30.8%) |
| Jun 2005 | - | $172.14M(-10.4%) |
| Mar 2005 | - | $192.22M(-11.1%) |
| Dec 2004 | $211.68M(+20.6%) | - |
| Sep 2004 | - | $216.28M(+42.2%) |
| Jun 2004 | - | $152.10M(-6.5%) |
| Mar 2004 | - | $162.70M(-7.3%) |
| Dec 2003 | $175.46M(-9.3%) | - |
| Dec 2003 | - | $175.46M(-1.0%) |
| Sep 2003 | - | $177.29M(-0.2%) |
| Jun 2003 | - | $177.71M(-0.4%) |
| Mar 2003 | - | $178.37M(-8.6%) |
| Dec 2002 | $193.36M(-12.9%) | - |
| Sep 2002 | - | $195.10M(-5.7%) |
| Jun 2002 | - | $206.95M(+18.3%) |
| Mar 2002 | - | $174.98M(-16.4%) |
| Mar 2001 | - | $209.25M |
| Dec 2000 | $222.03M | - |
FAQ
- What is Genmab A/S annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Genmab A/S?
- What is Genmab A/S annual cash & cash equivalents year-on-year change?
- What is Genmab A/S quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Genmab A/S?
- What is Genmab A/S quarterly cash & cash equivalents year-on-year change?
What is Genmab A/S annual cash & cash equivalents?
The current annual cash & cash equivalents of GMAB is $2.93B
What is the all time high annual cash & cash equivalents for Genmab A/S?
Genmab A/S all-time high annual cash & cash equivalents is $4.17B
What is Genmab A/S annual cash & cash equivalents year-on-year change?
Over the past year, GMAB annual cash & cash equivalents has changed by -$1.24B (-29.72%)
What is Genmab A/S quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of GMAB is $2.90B
What is the all time high quarterly cash & cash equivalents for Genmab A/S?
Genmab A/S all-time high quarterly cash & cash equivalents is $4.28B
What is Genmab A/S quarterly cash & cash equivalents year-on-year change?
Over the past year, GMAB quarterly cash & cash equivalents has changed by +$637.99M (+28.22%)